BioNexus Gene Lab (BGLC) Non-Current Assets (2018 - 2026)

BioNexus Gene Lab has disclosed Non-Current Assets across 9 years of filings, most recently posting $3.8 million for Q2 2026.

• In Q2 2026, Non-Current Assets rose 24.36% year-over-year to $3.8 million; the TTM figure through Jun 2026 stood at $3.8 million (up 24.36% YoY), while the FY2025 annual figure was $3.8 million, up 26.66% from the prior year.
• Non-Current Assets came in at $3.8 million for Q2 2026 at BioNexus Gene Lab, down from $3.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.0 million in Q3 2024 to a low of $2.0 million in Q3 2025.
• Average Non-Current Assets over 5 years is $3.1 million, with a median of $3.0 million recorded in 2024.
• Year-over-year, Non-Current Assets surged 33.75% in 2023 and slumped 49.58% in 2025.
• Over 5 years, Non-Current Assets stood at $2.7 million in 2022, then increased by 23.35% to $3.4 million in 2023, then fell by 10.43% to $3.0 million in 2024, then grew by 26.66% to $3.8 million in 2025, then fell by 0.55% to $3.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $3.8 million in Q2 2026, $3.8 million in Q1 2026, and $3.8 million in Q4 2025.